HK1105993A1 - Anti-a33 antibody - Google Patents

Anti-a33 antibody

Info

Publication number
HK1105993A1
HK1105993A1 HK07111099.0A HK07111099A HK1105993A1 HK 1105993 A1 HK1105993 A1 HK 1105993A1 HK 07111099 A HK07111099 A HK 07111099A HK 1105993 A1 HK1105993 A1 HK 1105993A1
Authority
HK
Hong Kong
Prior art keywords
antibody
Prior art date
Application number
HK07111099.0A
Other languages
English (en)
Inventor
Shiro Kataoka
Takafumi Tomura
Noriko Otani
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of HK1105993A1 publication Critical patent/HK1105993A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
HK07111099.0A 2004-09-06 2007-10-15 Anti-a33 antibody HK1105993A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004259090 2004-09-06
PCT/JP2005/016576 WO2006028197A1 (ja) 2004-09-06 2005-09-02 抗a33抗体

Publications (1)

Publication Number Publication Date
HK1105993A1 true HK1105993A1 (en) 2008-02-29

Family

ID=36036478

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07111099.0A HK1105993A1 (en) 2004-09-06 2007-10-15 Anti-a33 antibody

Country Status (10)

Country Link
US (2) US7579187B2 (ja)
EP (2) EP2145954A1 (ja)
JP (2) JP4088655B2 (ja)
KR (1) KR100918746B1 (ja)
CN (1) CN101010427B (ja)
AU (1) AU2005280975B2 (ja)
CA (1) CA2579391C (ja)
HK (1) HK1105993A1 (ja)
TW (1) TW200621803A (ja)
WO (1) WO2006028197A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007311002B2 (en) * 2006-10-19 2012-01-12 Csl Limited Antibody antagonists of interleukin-13 receptor alpha 1
US7883705B2 (en) * 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
US8163285B2 (en) 2007-11-02 2012-04-24 Novartis Ag Nogo-A binding molecules and pharmaceutical use thereof
CN101888856B (zh) 2007-11-07 2014-08-27 塞尔德克斯医疗公司 结合人树突和上皮细胞205(dec-205)的抗体
BRPI0915667B8 (pt) 2008-07-08 2021-05-25 Geneuro Sa ligante, fragmentos scfv e fab, anticorpo, composição farmacêutica, ácido nucleico, molécula de ácido nucleico, vetor, célula hospedeira, método para produção do ligante, ligante, composição farmacêutica, método de detecção do antiligante em uma amostra biológica e kit de imunoensaio para detecção do antiligante em uma amostra biológica
EP2917236A2 (en) * 2012-11-06 2015-09-16 MedImmune, LLC Combination therapies using anti-pseudomonas psl and pcrv binding molecules
AU2013370171B2 (en) * 2012-12-28 2018-09-13 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
US11746159B2 (en) 2015-02-10 2023-09-05 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies
CN110540591A (zh) * 2019-08-09 2019-12-06 无锡傲锐东源生物科技有限公司 一种抗糖蛋白A33（Glycoprotein A33）单克隆抗体及其免疫检测应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0199141A3 (en) * 1985-04-19 1988-07-20 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancer
US5851526A (en) * 1985-04-19 1998-12-22 Ludwig Institute For Cancer Research Methods of treating colon cancer utilizing tumor-specific antibodies
US5160723A (en) * 1985-04-19 1992-11-03 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
US5431897A (en) * 1985-04-19 1995-07-11 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB2278357B (en) * 1992-12-10 1997-03-05 Celltech Ltd Humanised antibodies directed against A33 antigen
US6307026B1 (en) * 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
WO2001030393A2 (en) 1999-10-22 2001-05-03 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products
MXPA03004793A (es) 2000-11-30 2004-12-03 Medarex Inc Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos.
US6643550B2 (en) * 2000-12-15 2003-11-04 Cardiac Pacemakers, Inc. Multi-polar connector
JP2004259090A (ja) 2003-02-27 2004-09-16 Toshiba Corp 情報処理装置および情報処理方法
US7432359B2 (en) * 2004-09-06 2008-10-07 Kirin Pharma Kabushiki Kaisha Anti-A33 antibody
JP4976741B2 (ja) * 2006-05-16 2012-07-18 株式会社東芝 平面アンテナ

Also Published As

Publication number Publication date
JPWO2006028197A1 (ja) 2008-05-08
KR20070088570A (ko) 2007-08-29
AU2005280975A1 (en) 2006-03-16
US20070141054A1 (en) 2007-06-21
US7579187B2 (en) 2009-08-25
CN101010427B (zh) 2011-07-27
CA2579391C (en) 2010-10-26
CN101010427A (zh) 2007-08-01
US20090299039A1 (en) 2009-12-03
JP4088655B2 (ja) 2008-05-21
EP1801208A1 (en) 2007-06-27
TW200621803A (en) 2006-07-01
AU2005280975B2 (en) 2009-06-18
WO2006028197A1 (ja) 2006-03-16
CA2579391A1 (en) 2006-03-16
EP2145954A1 (en) 2010-01-20
KR100918746B1 (ko) 2009-09-24
TWI359154B (ja) 2012-03-01
EP1801208A4 (en) 2009-04-01
JP2008138004A (ja) 2008-06-19

Similar Documents

Publication Publication Date Title
HK1218126A1 (zh) 抗體
IL181575A0 (en) Anti-ox40l antibodies
IL228033A0 (en) Antibodies
IL187106A (en) Sclerostin binds antibody
IL190472A0 (en) Anti-glypican-3 antibody
IL185366A0 (en) Antibody
GB0517487D0 (en) Antibodies
HK1105993A1 (en) Anti-a33 antibody
GB0420466D0 (en) Anti-glucan antibodies
ZA200701952B (en) Anti-OX40L antibodies
EP1780221A4 (en) ANTI-SYNOVIOLIN ANTIBODY
EP1896047A4 (en) ANTI-GFRALPHA3 ANTIBODIES
GB0505489D0 (en) Antibodies
GB2416348B (en) Carrying case
GB0418415D0 (en) Antibody
GB0512278D0 (en) Antibodies
GB0505054D0 (en) Antibodies
GB0420771D0 (en) Antibody
GB0402641D0 (en) Antibodies
GB0402642D0 (en) Antibodies
GB0413479D0 (en) Novel antibodies
GB0406914D0 (en) Assays
GB0425760D0 (en) Assays
GB0500400D0 (en) Antibody
GB0519883D0 (en) Antibodies

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150902